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Abstract 
 
Background: Fatigue, sleep disorders and neuropsychiatric symptoms are frequently 
reported in patients affected by Multiple Sclerosis (MS). The relationships between these 
symptoms are not yet fully understood and their management is difficult in clinical 
practice. This study was aimed to evaluate the frequency of fatigue, anxiety, depression, 
vitamin D deficiency and sleep disturbances in patients with MS from our outpatient MS 
clinic. 
Methods: This cross-sectional study sample consisted of 78 adult MS patients. They were 
analyzed on both their clinical features (type of MS, disease duration, clinical severity, 
type of treatment, psychiatric medication) and specific scales scores (Expanded Disability 
Status Scale, Modified Fatigue Impact Scale - MFIS, Hospital Anxiety and Depression 
Scale- HADS, Epworth Sleepiness Scale - ESS, Sun exposure status scale). Vitamin D 
levels as measured by 25-hydroxyvitamin D (25-OH-D) serum concentration was 
obtained. 
Results: The prevalence of clinically significant fatigue was 50%; mean MFIS score was 
35.72 (SD 19.6), which was significantly higher than in healthy population. There was a 
strong linear correlation of fatigue with anxiety (r=0.681, p<0.005) and depression 
(r=0.780, p<0.005). Fatigue was progressively higher with increased clinical disability 
(p<0.001). Patients reporting insomnia had higher fatigue levels(p<0.023). Low vitamin 
D levels were seen in 42.6% of patients. Patients with depressive symptoms were more 
likely to report lower levels of present sun exposure (p<0.037). 
Conclusions: Fatigue is a very common symptom in our MS patients, our findings 
support that higher levels of MS disability are associated with increased fatigue and 
should be considered. Importantly, we found that fatigue, sleep disturbances and 
neuropsychiatric symptoms cluster together and should be recognized and managed in 
MS patients.  
Keywords 
Multiple sclerosis; Fatigue; Anxiety; Depression; Sleep disturbances; Vitamin D. 
 
Highlights 
 
 Fatigue is a prevalent symptom in patients with Multiple sclerosis.  
 Age, disease duration and clinical disability may impact MS-related fatigue. 
 There is a strong link between fatigue, anxiety, depression and poor sleep in MS. 
 Hypnotic medication can contribute to fatigue and should be avoided. 
1 Introduction 
 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system (CNS), that results from interactions between susceptibility genes and 
environmental factors. (Compston and Coles, 2008)  The clinical course can be variable, 
frequently causing several neurological symptoms such as weakness, sensory loss and 
ataxia but also depression and fatigue. (Compston and Coles, 2008) The first symptoms 
usually appear between ages 20 and 40 years, effectively representing the most common 
non-traumatic disabling neurological condition in young adults. (Compston and Coles, 
2008) 
Fatigue is one of the most prevalent complains in MS, affecting 50 to 74 percent 
of patients at some point in the disease course. (Hadjimichael et al. , 2008, Putzki et al. , 
2008, Weiland et al. , 2015, Wood et al. , 2013) Fatigue is viewed by many patients as 
one of their most debilitating symptoms. (Krupp et al. , 2010) MS-related fatigue is 
different from everyday fatigue, as such, occurs in a daily basis, increases during the day 
and does not change over time. (Koch et al. , 2008, Krupp, Serafin, 2010, Tellez et al. , 
2006, Wood, van der Mei, 2013) Notably, some authors (Runia et al. , 2015) suggest that 
fatigue can be present in patients with a clinically isolated syndrome (CIS) and increases 
the risk of developing MS.  
Fatigue usually is not associated with demographic factors such as age, gender 
and disease duration, nor use of immune-modifying therapies. (Hadjimichael, Vollmer, 
2008, Krupp, Serafin, 2010, Mills and Young, 2011, Putzki, Katsarava, 2008, Tellez, Rio, 
2006) Nonetheless, disease-related factors such as relapse rate, (Tellez, Rio, 2006) 
mobility impairment (Krupp, Serafin, 2010, Mills and Young, 2011, Tellez, Rio, 2006) 
and MS subtype (Hadjimichael, Vollmer, 2008, Krupp, Serafin, 2010, Mills and Young, 
2011) are associated in some studies with fatigue.  
Consequently, MS-related fatigue adversely affects Quality of Life (QoL), 
(Yamout et al. , 2013) and is  linked to early retirement and unemployment. 
(Hadjimichael, Vollmer, 2008, Krupp, Serafin, 2010, Mills and Young, 2011, Simmons 
et al. , 2010) While individual studies have provided clinical, demographic and 
neuroimaging evidence, no single relationship explains fatigue in patients with MS 
(pwMS) and on-going studies consider it is likely to be multidimensional in its nature. 
(Krupp, Serafin, 2010) Accordingly, fatigue is usually separated in two categories: 
primary fatigue thought to be directly involved with MS pathophysiology and secondary 
fatigue, explained by the consequences of the disease itself, such as sleep disturbances, 
depression, anxiety, medication, among others. (Krupp, Serafin, 2010, Mills and Young, 
2011, Wood, van der Mei, 2013) 
Vitamin D insufficiency has been extensively reported in pwMS (Ascherio et al. 
, 2010, Ascherio et al. , 2014) and has been hypothesised to be an environmental risk 
factor for MS. (Ascherio, Munger, 2010, Munger et al. , 2006) In fact, some suggest that 
vitamin D insufficiency could have a detrimental role not only on MS onset (Ascherio, 
Munger, 2014, Martinelli et al. , 2014, Munger, Levin, 2006) but also in its clinical course. 
(Ascherio, Munger, 2014, Fitzgerald et al. , 2015) 
Nevertheless, the relationship between MS-related fatigue and vitamin D has 
received mixed results, while some studies report lower levels of fatigue in vitamin D 
supplemented pwMS, (Achiron et al. , 2015, Weiland, Jelinek, 2015) others did not found 
this association. (Ashtari et al. , 2013, Kampman et al. , 2012, Knippenberg et al. , 2014, 
Runia, Jafari, 2015) The latter could be explained by methodological differences between 
studies.  
Depressive and anxiety symptoms are two variables that theoretically could 
influence MS-related fatigue. (Learmonth et al. , 2013) The frequency of anxiety and 
depression among pwMS have been estimated to be higher than the general population 
(Dahl et al. , 2009) and frequently cluster together with fatigue. (Koch, Uyttenboogaart, 
2008, Tellez, Rio, 2006, Wood, van der Mei, 2013) 
Sleep disturbances such as restless legs syndrome, chronic insomnia along with 
others occur more frequently in pwMS. This disorders are associated with excessive 
daytime sleepiness and can influence fatigue. (Krupp, Serafin, 2010) 
MS-related Fatigue is a major but neglected concern in pwMS. Thus, identifying 
variables that affect fatigue is important and potentially, the investigation of these 
associations may increase understanding of the pathophysiology mechanisms of fatigue 
in MS and ultimately help to develop effective treatments. 
 Therefore, the aim of this study is to investigate the prevalence and severity of 
fatigue in pwMS and its relationship with other clinical variables. 
2 Patients and Methods 
2.1 Study participants and design 
 
This was a cross-sectional analysis of adult patients with CIS suggestive of MS 
and patients with the clinical confirmed diagnosis of MS according with the revised 
McDonald criteria. (Polman et al. , 2011)  followed at the MS clinic of São João Hospital, 
Porto, Portugal. 
Between May 2016 and January 2017, patients who were scheduled to be seen by 
a physician for routine follow-up were asked to complete a questionnaire and undergo a 
neurological examination. Patients’ medical records were scanned to obtain data on 
demographics, clinical data, immunomodulatory treatments, use of medication that may 
confound fatigue assessment (including beta-blockers, beta-interferons, and medication 
with anti-cholinergic proprieties) or known symptomatic fatigue treatments (eg. 
Modafinil), antidepressants, antipsychotic and anxiolytic/hypnotic medications and 
presence of fatigue. Patients with serious cognitive impairment impeditive of answering 
questionnaires were excluded from the analysis. The Ethic Committee of São João 
Hospital, Porto, Portugal approved the study protocol and patients gave written informed 
consent prior to inclusion in the study. 
2.2 Study outcome measures 
2.2.1 Instruments 
 
Fatigue was assessed using the Portuguese version (Gomes, 2011) of the Modified 
Fatigue Impact Scale (MFIS). (MSCCPG, 1998) The MFIS consists of a self-
administered 21-item questionnaire, validated in Portuguese, that aims to evaluate 
different features of perceived fatigue. Patients are asked to rate on a 5-point Likert scale 
how often fatigue influenced them over the past 4 weeks; total score range from 0 to 84, 
with higher scores indicating severe fatigue. The MFIS was built specifically to assess 
the impact of fatigue in the daily lives of pwMS and has been extensively used in studies 
and clinical practice, (Hadjimichael, Vollmer, 2008, Learmonth, Dlugonski, 2013, 
Sumowski and Leavitt, 2014, Tellez, Rio, 2006) and has proven to be a reliable and 
precise instrument. (Learmonth, Dlugonski, 2013) A cut-off value of 38 is the consensus 
in the literature to distinguish fatigued from non-fatigued pwMS. (Braley and Chervin, 
2010)  
We also evaluated depressive and anxiety symptoms using the Hospital Anxiety 
and Depression questionnaire (HADS). The HADS consists of a validated in Portuguese, 
(Pais-Ribeiro et al. , 2007) self-administered 14-item questionnaire that aims to evaluate 
different psychological outcomes including 2 scales assessing depression (7 items) and 
anxiety (7 items) symptoms; sub-scores range from 0 to 21, with higher scores indicating 
severe depression and anxiety. Clinically significant symptoms are defined at a cut-off 
value of ≥ 8 for both subscales. 
Daytime sleepiness was evaluated using the Epworth Sleepiness Scale (ESS). The 
ESS consists of a validated in Portuguese, (Sargento et al. , 2015) self-administered 8-
item questionnaire, that aims to evaluate sleepiness or the propensity to fall asleep in 
everyday life situations. Patients are asked to rate on a 4-point Likert scale how often they 
doze in different settings; total score range from 0 to 24, with higher scores indicating 
greater propensity to fall asleep. Excessive daytime sleepiness is defined at a cut-off value 
of 11. Other relevant data included self-reported sleep habits. 
2.2.2 Vitamin D 
 
Vit D3 obtained from production in the skin and diet is metabolized into 25-
hydroxyvitamin D (25-OH-D) in the liver. The latter serum concentration has been used 
in the majority of studies to screen vitamin D status. (Ascherio, Munger, 2010, Holick, 
2007) 
Most patients provided a blood sample and serum concentration of 25-OH-D was 
measured; a cut-off value of ≤ 50 nmol/L and a cut-off value of ≤ 72 nmol/L were used 
to categorize patients with vitamin D deficiency and relative insufficiency respectively. 
(Holick, 2007) 
Measurement of past sun exposure through recall by adults has been shown to be 
a valid and reliable way of assessing indirectly Vitamin D status. (van der Mei et al. , 
2006) Sun Exposure status was calculated using a recall questionnaire (Hanwell et al. , 
2010) assessing daily time in sun and skin exposure (face, limbs, body) for the previous 
week; score ranges from 0 to 56 with higher scores indicating more time per week 
outdoors and with more skin exposed to the sun. 
2.3 Clinical data 
 
 Annualised relapse rate (Ascherio, Munger, 2014, Fitzgerald, Munger, 2015) was 
assessed through patients’ reported relapses at study visit and retrospectively, IV 
methylprednisolone treated relapses were checked using patients’ medical records. 
 To evaluate neurological impairment we used the Expanded Disability Status 
Scale (EDSS), a well-established method to quantify disability in MS. (Kurtzke, 1983) 
2.4 Statistical analysis 
 
Continuous variables were summarised using mean and standard deviation (SD) 
and categorical variables using number and percentage. The univariate relationships 
between continuous variables were assessed using Student t test and categorical variables 
were compared using the χ2 test. Correlation analysis with Pearson product-moment 
correlation coefficient (r) was used to assess the association of two continuous variables. 
Strength of the relationship between variables was considered small (r=0.10 to 0.29), 
medium (r=0.30 to 0.49) and large (r=0.50 to 1.0). A p value of ≤ 0.05 was considered 
statistically significant. IBM SPSS Statistics 23 (IBM corp., New York, USA) was used 
for the analysis.  
3 Results 
3.1 Participants 
 
Seventy-eight patients (51 women and 27 men) fulfilled the inclusion criteria and 
were included in the study. Mean age of the study sample was 38 (range 18-65 years). 
The mean disease duration was 7.0 years (range 0-23 years) with mean age at diagnosis 
30.4 (SD 10.7); mean EDSS was 1.6 (SD 1.5). Disease course was as follows: 55% 
participants with relapsing-remitting MS, 25% with secondary progressive MS and 20% 
with CIS. Participants characteristics according to fatigue levels are presented in Table 1. 
Table 1: Demographic, Clinical characteristics and treatment plans by fatigue severity. 
 Fatigue (n=33) No fatigue (n=32) p value 
Demographics    
   Mean age, years (sd)* 41 (10.7) 32 (9.9) <0.001 
   Gender, n (%)**   n.s. 
      Male 10 (45.5) 12 (54.5)  
      Female 23 (30.3) 20 (37.5)  
Clinical characteristics    
   Disease duration, mean (sd) (months)* 102 (84) 60 (56) < 0.021 
   Age at diagnosis, mean (sd) (years)* 32.06 (9.89) 26.77 (9.87) <0.038 
   MS subtype, n (%)**   n.s. 
      Relapsing remitting 16 (26.7) 15 (25)  
      Primary or secondary progressive 10 (16.7) 5 (8.3)  
      CIS 6 (10) 8 (13.3)  
   EDSS, mean (sd)* 1.96 (1.69) 1.05 (0.97) <0.015 
Treatment, n (%)    
   Immunomodulatory** 18 (28.6) 20 (31.7) n.s 
      Interferon beta 11 (17.2) 16 (25)  
      Glatiramer acetate 2 (3.1) 3 (4.7)  
      Dimethyl fumarate 5 (7.8) 2 (3.1)  
   Immunosuppressive** 9 (14.4) 10 (15.9) n.s 
      Natalizumab 5 (7.8) 6 (9.4)  
      Fingolimod 4 (6.3) 4 (6.3)  
   No treatment** 5 (7.9) 1 (1.6) n.s 
EDSS, Expanded Disability Status Scale; *t test ** χ2;  n.s, non-significant (p>0.05) 
 
Patients reporting fatigue were likely to be older. Blood samples for vitamin D 
measurements were available for 54 patients. The non-responders did not differ in mean 
age, gender distribution, disease duration from responders (data not shown). 
3.2 Fatigue 
 
Thirty-three patients (50%) suffered from fatigue, and the mean MFIS score for 
patients was 35.72 (SD 19.6). In healthy individuals from the literature(Gomes, 2011), 
the mean MFIS was 23 (SD 12.24) which was significantly lower than in our patients 
(p<0.0005). MFIS scores were not associated with gender. As shown in Table 1, fatigued 
patients were likely to be diagnosed at an older age, had longer disease duration, and more 
disability as reflected in the EDSS at inclusion consultation than non-fatigued patients. 
The prevalence and severity of fatigue was similar in patients with relapsing-remitting, 
secondary progressive and primary progressive MS. Fatigue levels did not differ between 
CIS patients and clinically definitive MS patients. 
3.3 Vitamin D 
 
The mean serum 25-OH-D concentration of patients was 31.53 ng/mL (SD 19.61). 
Twenty-three patients (42.6%) had low vitamin D levels (<29ng/mL) and 15 patients 
(27.8%) had vitamin D deficiency (<20ng/mL).  The mean 25-OH-D concentration 
among those with fatigue was 29.5 ng/mL (SD 13.3) and 35.0 ng/mL (SD 26.2) among 
non-fatigued patients as shown in table 2. 
Table 2: Scales scores, laboratory values and annualized relapse rate by fatigue severity. 
 Fatigue (n=33) No fatigue (n=32) p value 
Scales    
   HADS A, mean (sd)* 11 (3.9) 4.7 (2.6) <0.0005 
   HADS D, mean (sd)* 9 (2.8) 2.7 (2.5) <0.0005 
   ESS, mean (sd)* 3.2 (3.40) 2.5 (2.86) n.s 
Psychiatric medication, n (%)    
   Antidepressant** 14 (22.2) 5 (7.9) <0.035 
   Antipsychotic 7 (11.1) 0  
   anxiolytic/hypnotic** 9 (14.3) 3 (9.7) n.s 
   Sun exposure score, mean (sd)* 16.6 (5.35) 18.4 (4.5) n.s 
Laboratory values    
   25-OH-D, mean (sd), (ng/mL)* 29.5 (13.3) 35.0 (26.2) n.s 
Disease activity    
   Annualized relapse rate, n (%)* 10 (30.3) 7 (18.7) n.s 
HADS A and D, Hospital Anxiety and Depression Scale; ESS, Epworth Sleepiness Scale; 25-OH-D, 25-hydroxyvitamin D; *t test 
** χ2 ; n.s, non-significant (p>0.05) 
 
We found no association between 25-OH-D levels and presence of fatigue, anxiety 
or depression. Twenty-seven patients (34.6%) were taking vitamin D-containing 
supplement. 
3.4 Neuropsychiatric symptoms   
 
Fifty-nine patients (75.6%) reported clinically significant neuropsychiatric 
symptoms: anxiety was reported by 39.7% of patients and depressive symptoms were 
present in 35.9%. There were no significant differences between gender. MFIS strongly 
correlated with both anxiety (r=0.681, p<0.005) and depression (r=0.780, p<0.005). (see 
table 2). Fatigue levels were significantly higher in patients using antidepressants, 
antipsychotic and anxiolytic/hypnotic medications 46.0 (SD 15.9) vs 28.9 (SD 19.04) 
(p<0.0005). Patients with clinically significant depressive symptoms were significantly 
more fatigued 49.7 (SD 13.0) vs 24.72 (SD 16.8) (p<0.0005). 
3.5 Treatment 
 
Forty-six patients (59%) were treated with immunomodulatory agents: 37.2% were 
on treatment with one of the INF-β preparations, GLA 10.3%, Dimethyl fumarate (DMF) 
10.3% or Teriflunamide 2,6%. Thirty-nine patients (50%) were treated with 
immunosuppressive agents: the most frequently used was Natalizumab 15.4% followed 
by Fingolimod 10.3%. Eleven patients (14.1%) were given Fampiridine and 5 patients 
were not under disease modifying treatment. Fatigue levels were not associated with any 
of the treatments plans, nor between treated and untreated patients (see table 2). Two 
patients (2.6%) were receiving pharmacological treatment for fatigue, namely modafinil. 
3.6 Sleep 
 
The mean total sleep time was approximately 10h (SD 3h), total sleep time did not 
differ between fatigued and non-fatigued patients and 43.6% of patients reported 
insomnia. Fatigue levels differ significantly between patients reporting insomnia 41.4 
(SD 18.2) vs 27.5 (SD 21.8) (p<0.023), similarly patients reporting insomnia had 
significantly more anxiety symptoms 9.5 (SD 4.5) vs 6.2 (SD 4.5) (p<0.018). There was 
no association between sleeping during the day and fatigue levels (see table 2). The 
prevalence of excessive daytime sleepiness was 3.8% and there was no correlation 
between fatigue and sleepiness as assessed by the ESS scores.  
3.7 Sun exposure 
 
There was no correlation between sun exposure indicators (vitamin D and Sun 
exposure score). Present sun exposure (hours) was not a predictor of vitamin D level or 
MFIS score. Patients with depressive symptoms were more likely to report lower levels 
of present sun exposure (p<0.037). 
3.8 Relapses 
 
In the year prior to the study, 10 relapses occurred in 30.3% of fatigued patients 
and 7 relapses involved 18.7% of non-fatigued patients (see table 2). Fatigue levels were 
not associated with annualized relapse rate. 
4 Discussion 
 
Although often discussed in recent years, the pathophysiology of fatigue in MS 
remains unclear. (Braley and Chervin, 2010, Induruwa et al. , 2012) Until today, no single 
relationship explains fatigue in pwMS and on-going studies consider it is likely to be 
multidimensional in its nature. Accordingly, fatigue is usually separated in two 
categories: primary or central fatigue thought to be directly involved with the pathogenic 
mechanisms of MS including immunological factors and central nervous system damage, 
such as pro-inflammatory cytokines, lesion load, compensatory brain reorganization, 
axonal injury and hormonal influences. (Braley and Chervin, 2010, Induruwa, 
Constantinescu, 2012) And secondary fatigue, explained by the consequences of the 
disease itself, such as sleep disorders, depression, anxiety, iatrogenicity, nociceptive pain 
among others. (Braley and Chervin, 2010, Krupp, Serafin, 2010) 
This cross-sectional study aimed to determine fatigue prevalence in pwMS and its 
relation with several clinical variables using validated questionnaires and objective 
clinical assessment. Our study adds to the current knowledge about fatigue in pwMS since 
few previous studies have reported secondary conditions that contribute to fatigue.  
The prevalence of clinically significant fatigue, depression and anxiety was 50%, 
35.9% and 39.7% respectively. 43.6% of patients reported sleep problems.  
The high prevalence of clinically significant fatigue (50%) reported here is 
consistent with previous studies that shown similar results (Hadjimichael, Vollmer, 2008, 
Putzki, Katsarava, 2008, Weiland, Jelinek, 2015, Wood, van der Mei, 2013) and 
demonstrates that MS-related fatigue impacts activities of daily living as assessed by the 
MFIS. Our assessment of fatigue levels revealed that patients differed on several disease 
characteristics: fatigued patients were older, had a longer disease course and suffered 
from greater clinical disability. Notably, fatigued patients were likely to be diagnosed at 
an older age. Furthermore, as previously described, (Mills and Young, 2011, Putzki, 
Katsarava, 2008) we did not find differences in gender for fatigue levels. 
Such findings are consistent with large investigations that linked older age and 
disease duration (Hadjimichael, Vollmer, 2008) with increased fatigue levels in pwMS. 
We found that fatigued patients also had increased disability levels as assessed by the 
EDSS, which is in line with previous studies that found a clear increase in fatigue with 
higher mobility impairment (Hadjimichael, Vollmer, 2008) and MS impact. (Mills and 
Young, 2011) It is important that clinicians recognize fatigue in pwMS even in those with 
reduced ambulation. 
In our study, fatigue occurred among patients of all MS subtypes including CIS 
patients and there was no significant association in MS subtype with the level of fatigue. 
We agree with previous studies that found that MS-related fatigue occurs independently 
of the type of MS and can be present at the time of CIS. (Runia, Jafari, 2015)  
There have been only a few studies evaluating the effect of immune-modifying 
therapies and fatigue. We compared treatment modalities and found no difference 
between individuals on different immune-modifying therapies. Additionally, we found 
no relationship between fatigue levels in treated versus untreated patients. These findings 
are in keeping with previous studies. (Hadjimichael, Vollmer, 2008, Putzki, Katsarava, 
2008) 
Our assessment revealed no important influence of continuous 25-OH-D serum 
levels nor recently reported sun exposure on fatigue levels. Patients who had Vitamin D 
deficiency (<20ng/mL) were no more fatigued than vitamin D sufficient patients. 
Although vitamin D deficiency has strongly been linked to MS risk (Martinelli, Dalla 
Costa, 2014, Munger, Levin, 2006) progression and activity, (Ascherio, Munger, 2010) 
the evidence for the influence of vitamin D serum levels on MS-related fatigue is sparse. 
A longitudinal study (Knippenberg, Damoiseaux, 2014) found no relationship between 
vitamin D levels and MS-related fatigue, interestingly, they did however, found that 
higher self-reported sun exposure was related to lower levels of fatigue.  
In the present study, patients with depressive symptoms were more likely to report 
lower levels of present sun exposure. It is conceivable that pwMS experiencing more 
depression symptoms could refrain from outdoor activities and this could account for the 
apparent relationship between sun exposure and fatigue. A randomized controlled trial 
(Achiron, Givon, 2015) found that vitamin D supplementation decreased fatigue levels 
on severely fatigued pwMS. We did not found such association as vitamin D 
supplemented patients experienced similar fatigue levels vs non-supplemented patients. 
The prevalence of neuropsychiatric symptoms reported here is similar to that 
previously reported in MS (Dahl, Stordal, 2009, Knippenberg, Damoiseaux, 2014, Wood, 
van der Mei, 2013) and considerably higher than was reported in non-MS population. 
(Dahl, Stordal, 2009) In a population-based study, (Dahl, Stordal, 2009) a significant 
proportion of pwMS reported anxiety (30.2%) and depressive symptoms (25.7%). 
Previously there have been conflicting results between the relationship of anxiety and 
depressive symptoms with fatigue in pwMS, while it has been proven that the overlap of 
these symptoms are higher than the expected, (Wood, van der Mei, 2013) some studies 
found a weak correlation between these symptoms, (Mills and Young, 2011) with the 
association largely confined to woman. (Dahl, Stordal, 2009) A longitudinal study (Koch, 
Uyttenboogaart, 2008) found that fatigue and depressive symptoms occurred together in 
40% of pwMS and prevailed at the same intensity for 10 years of follow-up. The 
disagreement in the literature may be due to variability in defining and measuring fatigue 
levels or differences in patients’ population. 
In the present study, we found a strong linear correlation between fatigue and both 
anxiety and depressive symptoms. The concurrence of fatigue and neuropsychiatric 
symptoms was expected since not only is depression itself associated with similar 
symptoms (loss of motivation, anhedonia), (Braley and Chervin, 2010, Krupp, Serafin, 
2010) but this association could occur due to similar pathogenic mechanisms and may 
involve gray matter atrophy of specific brain regions (Gobbi et al. , 2014, Nygaard et al. 
, 2015) making this intimate relationship even more complex. Similarly, in this study, 
patients receiving psychiatric medication were likely to be more fatigued. This apparent 
association could be explained by the overlap of fatigue and depressive symptoms and 
therefore, more likely to be selected for these treatments. However, this could also entail 
that regardless of any contributory part of depressive symptoms to fatigue, psychiatric 
medication was not particularly effective in fatigue. Aside from the contributing part of 
neuropsychiatric symptoms to fatigue, these symptoms are associated with substantial 
suicidal risk (Jose Sa, 2008) and therefore, the presence of fatigue should raise clinical 
awareness for these symptoms and thereby promote their evaluation and treatment.  
We found that fatigue levels and anxiety symptoms were higher in patients 
reporting insomnia, these findings are in keeping with the literature where it seems that 
disrupted nocturnal sleep may contribute to fatigue in MS. (Mills and Young, 2011) Sleep 
disturbances are more common in pwMS than the general population (Braley and 
Chervin, 2010, Brass et al. , 2014, Krupp, Serafin, 2010) and the rate of chronic insomnia 
is reported to be 31.6% by the largest study to date. (Brass, Li, 2014) Not only are specific 
conditions such as central sleep apnea, restless legs syndrome, narcolepsy more 
frequently present in pwMS (Braley and Chervin, 2010, Brass, Li, 2014) which are often 
associated with fatigue, but also poor sleep may arise from MS-related symptoms, 
(Krupp, Serafin, 2010) these include neuropsychiatric symptoms, spasticity, nocturia and 
iatrogenicity. (Braley and Chervin, 2010, Brass, Li, 2014, Krupp, Serafin, 2010) The 
association between sleep disturbances and fatigue is still in debate, a recent study (Mills 
and Young, 2011) demonstrated a link between sleep and MS-related fatigue, suggesting 
a “V” shape relationship between duration of nocturnal sleep and fatigue, being 7.5h of 
total sleep time associated with the lowest levels of fatigue and both lower and higher 
sleep times being deleterious. They also found a weak correlation between sleepiness as 
assessed by the ESS and fatigue. Severe fatigue levels in pwMS should prompt the 
physician for the possibility of underlying sleep disturbances which should be addressed 
and treated. In this matter, in the present study, patients receiving hypnotic medication, 
which is frequently used to improve nocturnal sleep, was actually detrimental to fatigue. 
This apparent contradiction can be explained by the difficulty to differentiate between 
fatigue and daytime somnolence (Braley and Chervin, 2010) that could be being reported, 
and carryover effects from hypnotic use could be influencing fatigue levels, and for this 
reason, physicians should promote alternative treatments for insomnia in pwMS. (Braley 
et al. , 2015) 
The strength of our study is that patients were examined at our outpatient 
department which enabled us to obtain a clinical assessment of fatigue related variables. 
A limitation of our study is its cross-sectional design. Since data were not collected 
prospectively, a longitudinal evaluation of fatigue is not possible and it is possible that 
our findings could be attributed to reverse causality. Nevertheless, our findings are in 
agreement with previous studies.  
5 Conclusions 
 
In conclusion, half of pwMS in our sample reported severe fatigue that impacts 
patients’ daily lives. Presence of fatigue and its severity were associated with age, disease 
duration and clinical disability and seems to be relatively independent of MS subtype and 
treatment modality. We suggest that poor sleep, anxiety and depressive symptoms and 
psychiatric medication are significantly associated with fatigue in pwMS. 
Neuropsychiatric symptoms overlapped with fatigue. These findings suggest that non-
central causes could have a substantial contribution to MS-related fatigue and should be 
actively investigated and treated.   
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should be documented in the paper. Appropriate consents, permissions and releases must be obtained
where an author wishes to include case details or other personal information or images of patients
and any other individuals in an Elsevier publication. Written consents must be retained by the author
and copies of the consents or evidence that such consents have been obtained must be provided to
Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or
Personal Information of Patients or other Individuals. Unless you have written permission from the
patient (or, where applicable, the next of kin), the personal details of any patient included in any
part of the article and in any supplementary materials (including all illustrations and videos) must
be removed before submission.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/msard/
Referees
Please submit the names and institutional e-mail addresses of several potential referees. For more
details, visit our Support site. Note that the editor retains the sole right to decide whether or not the
suggested reviewers are used.
PREPARATION
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NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation
and uploading of your files. The system automatically converts your files to a single PDF file, which
is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file
to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-
out that can be used by referees to evaluate your manuscript. It should contain high enough quality
figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at
the initial submission. Please note that individual figure files larger than 10 MB must be uploaded
separately.
References
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct.
Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements
needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and
Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in
your initial submission for peer review purposes.
Divide the article into clearly defined sections.
Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text
in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should
be placed directly below the figure or table.
REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. The electronic text should be prepared
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with
Elsevier). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
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Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that the e-mail address is given and that contact
details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A structured abstract that includes the headings: Background, Methods, Results, and Conclusion is
required. The abstract must not exceed 500 words. Background. The background should provide
a brief and concise description of the background and reason for the study citing relevant literature
overview, and a clear statement of hypothesis, and study objectives. The introduction should not be
an exhaustive review of the literature. Methods. This section provides a concise description of the
procedural, experimental, and statistical methods in sufficient detail to allow other investigators to
reproduce the study. Results. State concisely the results of the study. Conclusion. Briefly summarize
the major conclusions of the investigation.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images and in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that
convey the core findings of the article and should be submitted in a separate editable file in the
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points
(maximum 85 characters, including spaces, per bullet point). You can view example Highlights on
our information site.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
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Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in
line with normal text where possible and use the solidus (/) instead of a horizontal line for small
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often
more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors build footnotes into the text, and this feature may be used. Should this not be the case,
indicate the position of footnotes in the text and present the footnotes themselves separately at the
end of the article.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a
single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
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Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators
can produce scientific, technical and medical-style images, as well as a full range of charts, tables
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve
them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but
explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference management software
This journal has standard templates available in key reference management
packages EndNote http://www.endnote.com/support/enstyles.asp and Reference Manager
http://refman.com/support/rmstyles.asp. Using plug-ins to wordprocessing packages, authors only
need to select the appropriate journal template when preparing their article and the list of references
and citations to these will be formatted according to the journal style which is described below.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
A DOI can be used to cite and link to electronic articles where an article is in-press and full citation
details are not yet known, but the article is available online. A DOI is guaranteed never to change,
so you can use it as a permanent link to any electronic article. An example of a citation using DOI
for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M.
(2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal
of Geophysical Research, http://dx.doi.org/10.1029/2001JB000884i. Please note the format of such
citations should be in the same style as all other references in the paper.
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Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/multiple-sclerosis-and-related-disorders
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of
publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first
alphabetically, then chronologically.
Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al.
(2010) have recently shown ....'
List: References should be arranged first alphabetically and then further sorted chronologically if
necessary. More than one reference from the same author(s) in the same year must be identified by
the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci.
Commun. 163, 51–59.
Reference to a book:
Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York.
Reference to a chapter in an edited book:
Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S.,
Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.
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Reference to a website:
Cancer Research UK, 1975. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/ (accessed 13.03.03).
Reference to a dataset:
[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak
wilt disease and surrounding forest compositions. Mendeley Data, v1. http://dx.doi.org/10.17632/
xwj98nb39r.1.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum size
of 150 MB. Video and animation files supplied will be published online in the electronic version of your
article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can
choose any frame from the video or animation or make a separate image. These will be used instead
of standard icons and will personalize the link to your video data. For more detailed instructions please
visit our video instruction pages. Note: since video and animation cannot be embedded in the print
version of the journal, please provide text for both the electronic and the print version for the portions
of the article that refer to this content.
Patient Details
Every video submission must consist of high-resolution images and a consent form for publication for
educational purposes signed by the patient see form, please see the Patient Details section below.
The Editors reserve the right to ask for additional video/s or video modifications.
Patient Details Studies on patients or volunteers require ethics committee approval and informed
consent, which should be documented in your paper.
If you wish to include images of patients or case details in an Elsevier publication, you will need to
adhere to the following requirements:
In order to comply with data protection and privacy rules, each individual who appears in any
video, recording, photograph or case report must be made aware in advance of the fact that such
photographs are being taken or such video, recording or report is being made and of all of the purposes
for which you wish to use them and that individual (or next of kin in the case of children) must give his/
her explicit written consent. If such consent is made subject to any conditions (for example, adopting
measures to prevent personal identification of the person concerned), Elsevier must be made aware
of all such conditions. Written consents must be provided to Elsevier on request.
The author is responsible for obtaining all necessary consents from patients for (i) the performance of
any medical procedure involved, as well as (ii) a release permitting our use of the relevant material.
It is our insurers' preference that we do not have any direct contractual relationship with the patients
themselves. Please download the Patient consent form here
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
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and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
AFTER ACCEPTANCE
Availability of accepted article
This journal makes articles available online as soon as possible after acceptance. This concerns the
accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or
proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable
by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is
an unedited article. Subsequent production stages will simply replace this version.
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
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